MURATA-MANUFACTURING
24.3.2021 04:02:13 CET | Business Wire | Press release
In April, Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) will begin a service in Indonesia that will provide data from a traffic counter system mapping traffic volume via local service providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005470/en/
The system developed by Murata uses LiDAR technology*1 which has superior environmental adaptability compared to cameras, for its main sensor in order to adapt to changing analytical conditions, such as rain or darkness. With high-precision sensing, the system can reliably generate not only traffic volume data, but also traffic data that classifies vehicle-type information, such as passenger cars and large vehicles. This enables strategic advertising tailored to the desired time frame and vehicle-type data, for example, by displaying ads for specific products for B2B targets during commuting hours. By mapping regional traffic volumes, the system is also expected to see increased use as reference data for city planning, such as for the construction of shopping malls in locations with significant traffic levels.
The data provision service based on this system will start in Indonesia and later expand to the ASEAN region including Thailand and Malaysia.
The president of Murata Manufacturing, Norio Nakajima, issued the following statement.
“As a comprehensive electronic components maker, Murata Manufacturing since its founding has created products to support our customers who work in communications. As the digital transformation*2
continues globally, we are striving to not only provide electronic components and devices as before, but also to develop new digital business, including the provision of sensing data that will contribute to concrete solutions. We are working on boosting the digital information infrastructure in Southeast Asia with this new system and will contribute to the development of data visualization and digital transformation in countries around the world.”
Characteristics of the Traffic Counter System
- Uses LiDAR technology with high positioning performance as its sensor unit. Conducts stable measurements even under conditions such as rain and darkness, simultaneously capturing targets’ movement speed and volume, and classifying vehicles on the road.
- In addition to predicting rain based on CO2 and atmospheric pressure sensors, digitizes environmental data of the roads.
- Provides predictive rain data in pre-determined areas by analyzing environmental information.
- Customizable sensor functions responsive to client needs based on housing design that ensures extensibility.
- Creates a mesh network at a low cost.
- Can be implemented into existing infrastructure such as streetlights and pedestrian bridges.
- Provides analytical data via a dedicated cloud server.
- Gathers road traffic and environmental data captured with installed sensors provides real-time data and data processed via original algorithms, on a dedicated cloud server.
For details, please watch this video about the traffic counter system .
*1 Technology that measures the distance to a target by shining a laser on it and capturing the reflected laser light with an optical unit.
*2 The transformation of society and people’s lives for the better through the spread of information technology
Murata in Brief
Murata Manufacturing Co., Ltd. is a worldwide leader in the design, manufacture and sale of ceramic-based passive electronic components & solutions, communication modules and power supply modules. Murata is committed to the development of advanced electronic materials and leading edge, multi-functional, high-density modules. The company has employees and manufacturing facilities throughout the world. For more information, visit Murata's website at www.murata.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005470/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
